Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.

Abstract excerpt

A predictive population pharmacokinetic model was developed for a novel cyclooxygenase-2 (COX-2) inhibitor CS-706, using data from 130 subjects in 3 phase 1 trials after single or multiple doses of CS-706 (2- to 800-mg doses daily, up to 14 days) and validated using sparse data from a separate study. A 2-compartment model described the data. Typical apparent clearance (CL/F) was 47.2 L/h and was reduced by 43% at...

Topics

Join the communities discussing this publication.

• Cyclooxygenase 2 Inhibitors
• Cytochrome P-450 CYP2C19
• Cytochrome P-450 CYP2C9
• Cytochrome P-450 CYP2D6
• Double-Blind Method